Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial of Recombinant Hepatitis E Vaccine

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Xiamen Innovax Biotech Co., Ltd
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
National Institute of Diagnostics and Vaccine Development in infectious disease
Jiangsu Provincial Center for Disease Control and Prevention
Information provided by (Responsible Party):
Jun Zhang, Xiamen University
ClinicalTrials.gov Identifier:
NCT01014845
First received: November 13, 2009
Last updated: February 21, 2014
Last verified: February 2014

November 13, 2009
February 21, 2014
August 2007
June 2017   (final data collection date for primary outcome measure)
Rate of confirmed hepatitis E cases [ Time Frame: One year since one month post the third injection ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01014845 on ClinicalTrials.gov Archive Site
  • IgG anti-HEV seroconversion rate [ Time Frame: On one month post the third injection ] [ Designated as safety issue: No ]
  • Persistency of IgG anti-HEV [ Time Frame: One year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Clinical Trial of Recombinant Hepatitis E Vaccine
A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine

The primary purpose of this study is to determine whether the preventive hepatitis E are effective in the prevention of hepatitis E occurring at least 30 days after the administration of the third dose of vaccine.

The secondary purpose of this study is to to evaluate the safety and immunogenicity and immunopersistence of the study vaccine.

The initial study is planed to be ended on month 19 and the results were analysed and used for registration purpose. The extended study will be continued to assess the long-term efficacy, immunogenicity and safety.

Participants were randomly allocated into two groups, one received Hepatitis E vaccine and the other received hepatitis B vaccine. The study was carried out with two stages. In the first stage (phase 3a), 2 645 subjects was enrolled and actively monitored for solicited adverse events for 1 month after each injection. Serum samples from all the subjects were collected on day 0, 7m, 13m, 19m and timely after then to evaluate the immunogenicity and immuno-persistency. In the second stage (phase 3b), another 109 959 subjects was enrolled and monitored for solicited adverse events for 1 month after each injection. Serum samples from 9764 subjects among the phase 3b participants were collected on day 0, 7m, 19m and timely after then to evaluate the immunogenicity and immuno-persistency. Serious adverse events during the trial were followed up.

Suspected hepatitis cases were identified through an established active hepatitis surveillance system. The sentinels of the system comprised all the healthcare facilities in the field. Suspected hepatitis was defined as when patients presented with systemic symptoms such as fatigue and/or loss of appetite for more than 3 days with alanine aminotransferase (ALT) exceeding 2.5 fold upper limit of normal range (ULN). Paired sera were obtained from these patients at the time of presentation and 2-6 weeks later. Sera were tested for the HEV antibodies and HEV-RNA.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Hepatitis E
  • Biological: hepatitis E vaccine
    Intramuscularly given at 0, 1, 6m for three doses.
    Other Name: Hecolin
  • Biological: Hepatitis B vaccine
    Intramuscularly given at 0, 1, 6m for three doses.
  • Experimental: Hepatitis E vaccine
    Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
    Intervention: Biological: hepatitis E vaccine
  • Placebo Comparator: HBV vaccine
    Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
    Intervention: Biological: Hepatitis B vaccine

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
112604
June 2017
June 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy people aged from 16 years to 65 years old at the time of the first vaccination, normal intelligence and agree to sign the informed consent form.
  • Subjects will reside in the study region in the next 19 months.
  • Free of history of hepatitis B or hepatitis E.
  • Can comply with the request of study.
  • Axillary temperature is below 37 degree centigrade.

Exclusion Criteria:

For dose 1:

  • Having other vaccine or immunoglobulin within two weeks;
  • Having allergic history to vaccine and medicine
  • Eclampsia, epilepsy, encephalopathy and history of mental disease or family;
  • Thrombocytopenia or other disturbance of blood coagulation which would lead to muscle injection taboo;
  • Fixed or suspected deficiency of immunologic function, containing immunosuppressant treatment(radiation therapy, chemical treatment, steroid hormone, antimetabolites, cytotoxic drugs), genetic defect(e.g. fabism), HIV or other factors;
  • congenital malformation, eccyliosis or severe chronic disease(e.g. Down Syndrome, diabetes, sickle cell anemia or mental disease);
  • fixed or suspected other disease including fever, active infection, liver and kidney disease, angiocardiopathy, malignancy, acute and chronic disease;
  • joining other clinical study undergoing;
  • women pregnant or in lactation.

For dose 2 or 3:

  • Severe allergy for dose 1 or 2;
  • Severe adverse reaction associated with last vaccination;
  • New occurrence of symptoms meet dose 1 exclusion criteria after the first dose.
Both
16 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01014845
Pro-HE-003, 2006AA02A209
Yes
Jun Zhang, Xiamen University
Xiamen University
  • Xiamen Innovax Biotech Co., Ltd
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • National Institute of Diagnostics and Vaccine Development in infectious disease
  • Jiangsu Provincial Center for Disease Control and Prevention
Study Director: Jun Zhang, M.D. National Institute of Diagnostics and Vaccine Development in infectious disease, Xiamen University
Principal Investigator: Feng-Cai Zhu, M.D. Jiangsu Provincial Center for Disease Control and Prevention, China
Xiamen University
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP